ClinicalTrials.gg
CompletedNCT04126473Updated Aug 21, 2023

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

A Phase 2 interventional study of ELX-02 and Ivacaftor in Cystic Fibrosis, sponsored by Eloxx Pharmaceuticals, Inc.. Completed at 9 sites in 3 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by Eloxx Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Cystic Fibrosis with a site in Israel — 2 open to participants now, 3 under way, 1 of them phase 3. Cystic Fibrosis · Israel.

Enrollment
49th of 53
17 · median 121
Started
2019
with 2 others
Phase 2
10 of 62
1 open now
Registered
50th of 62
by date

Among the 62 studies in Cystic Fibrosis with a site in Israel, this one is the 49th largest by enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2019, is one of 10 in phase 2, and was the 50th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

2 of the 62 studies in Cystic Fibrosis with a site in Israel are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Cystic Fibrosis with a site in Israel, or all of them as a file.
02

Study summary

This is a Phase 2 open label study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 with and without ivacaftor in patients with CF with at least one G542X allele or phenotypically similar nonsense allele.

Up to 16 patients will be enrolled in the trial; up 4 patients will be homozygotes to G542X, and the remaining patients will be compound heterozygotes with G542X or phenotypically similar nonsense mutation and any Class 1 or Class 2 mutation.

Each patient will receive 5 escalating doses as follows:

  • 0.3 mg/kg per day SC
  • 0.75 mg/kg per day SC
  • 1.5 mg/kg per day SC
  • An individualized dose, as high as 3.0 mg/kg per day SC, based upon the patients observed safety and tolerability, PK at previous doses and the results of laboratory tests
  • ELX-02 1.5 mg/kg per day SC plus 150 mg ivacaftor every 12 bid
03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • aminoglycoside
  • Nonsense Mutation
  • Translational read through
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients must meet the following criteria to participate in this study:

  1. Males and females age 18 years and above in Germany and Israel; in countries where permitted, males and females age 16 years and above
  2. A confirmed diagnosis of nmCF with a documented G542X or phenotypically similar nonsense mutation, homozygote, or compound heterozygote with one of the specified mutations. For heterozygotes, one mutation has to be G542X or phenotypically similar nonsense mutation, and the second mutation could be and Class 1 or Class 2 mutation. Patients with one G542X or phenotypically similar nonsense allele and a second allele that is not in the above list may be potentially allowed but only after discussion on a case by case basis with and written approval from the Sponsor.
  3. Documented SCC ≥ 60 mEq/L
  4. ≥ 40% predicted normal for age, gender and height at Screening (Knudson Equation)
  5. (BMI) of 19.0 to 30.0 kg/m2 (inclusive).

Patients with any of the following characteristics/conditions will not be included in the study:

  1. Participation in clinical study including administration of any drug or device in the last 30 days or 5 half-lives (whichever is longer) prior to investigational product dosing in the current study
  2. History of any organ transplantation
  3. Major surgery within 180 days (6 months) of Screening
  4. Patients without documented prior aminoglycoside exposure who have a mitochondrial mutation that has been shown to increase sensitivity to aminoglycosides
  5. Known allergy to any aminoglycoside
  6. Patients with any abnormality at ENT screening, that indicates the presence of a vestibular toxicity associated with prior exposure to aminoglycosides.
  7. Dizziness Handicap Inventory (DHI)-H score at screening >16
  8. Patients receiving CFTR modulators within 2 months of study treatment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    ELX-02

    Eukaryotic ribosomal selective glycoside (ERSG)

    Drug: ELX-02 · Drug: Ivacaftor

Interventions

  • DrugELX-02

    ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).

  • CFTR potentiator

06

What researchers measure

Primary outcomes

  1. AEs associated with different dose levels of ELX-02

    Time frame: From the time of first dosing through the follow-up visit, an average of approximately 9 weeks

  2. Area under the plasma concentration curve from time zero to 24 hours (AUC0-24)

    Full PK profile 8 blood samples up to 24 hours

    Time frame: Day 1 of treatment periods 1, 2, 3, and 4

  3. Maximum observed plasma concentration (Cmax) on Day 1

    Full PK profile 8 blood samples over 24 hours

    Time frame: Day 1 of treatment periods 1, 2, 3, and 4

  4. Peak observed plasma concentration (Cpeak) over time

    Time frame: Days 1, 2 and 7 of treatment periods 1-3, Days 1, 2, 7, and 14 of treatment period 4, sparse sampling, blood sampling at 30 min and 1 hour post-dose

  5. Trough observed plasma concentrations (Cpredose) over time

    Time frame: Days 1, 2 and 7 of treatment periods 1-3, Days 1, 2, 7 and 14 of treatment period 4, sparse blood sampling at pre-dose

Secondary outcomes

  1. Changes from baseline in sweat chloride concentration

    Time frame: From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4

  2. Changes from baseline in percent predicted forced expiratory volume (ppFEV1)

    Time frame: From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4

  3. Changes from baseline in percent predicted forced vital capacity (ppFVC)

    Time frame: From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4

  4. Changes from baseline in percent predicted forced expiratory flow at 25-75% (ppFEF25-75)

    Time frame: From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4

07

Study locations

9 sites
  • The Royal Prince Alfred Hospital
    Camperdown, New South Whales 2050, Australia
  • The Royal Adelaide Hospital
    Adelaide, South Australia, Australia
  • The Alfred Hospital
    Melbourne, Victoria, Australia
  • Universitätsmedizin Essen Ruhrlandklinik
    Essen, North Rhine-Westphalia 45239, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt, Germany
  • Carmel Medical Center
    Haifa, Israel
  • Hadassah Medical Center
    Jerusalem, Israel
  • Schneider Children's Medical Center
    Petach Tikvah, Israel
  • Safra Children's Hospital - Chaim Sheba Medical Center
    Ramat Gan, Israel
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Apr 2022, 29 months.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 29 months is above that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2019
First posted
Oct 15, 2019
StartActual
Nov 5, 2019
Primary completionActual
Apr 6, 2022
CompletionActual
Apr 6, 2022
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04126473
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Oct 15, 2019
Start date
Nov 5, 2019
Primary completion
Apr 6, 2022
Completion
Apr 6, 2022
Last update
Aug 21, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ELX-02

Start the discussion